Pharmacogenetics-oriented therapeutic drug monitoring of digoxin in critically ill patients

Saudi Pharmaceutical Journal

Volumn 14, Issue 3-4, 2006, Pages 139-148

  Mohammed Ebid, Abdel Hameed I ^a   Mokhtar, Mohammed Sherif ^b   Abdel Shafi, SanA'A ^c   El Feky, Gina Samy ^d  

^a Ein Helwan   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

^d NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Digoxin; Gene polymorphism; Multi Drug Resistance 1 (MDR 1); p glycoprotein; Therapeutic Drug Monitoring (TDM)

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; CARDIXENE; CEFOPERAZONE; CLINDAMYCIN; DEXAMETHASONE; DIGOXIN; ENOXAPARIN; FUROSEMIDE; GENTAMICIN; METFORMIN; MULTIDRUG RESISTANCE PROTEIN 1; OMEPRAZOLE; RANITIDINE; VITAMIN B COMPLEX; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DNA EXTRACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; OUTCOME ASSESSMENT; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STEADY STATE;

EID: 33845659935     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ensom MHH., Chang TKH., Patel P.; Pharmacogenetics: The therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40 (11): 783-802.
2. Almuete VL.: Drug therapy and pharmacogenomics. APhA 2000-American Pharmaceutical Association Annual Meeting. Available from URL:http://www. medscape.com/medscape/CNO/2000/APHA/APHA-0.3.html [Accessed 2003 august 1]
3. Evans WE., Relling MV.: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491.
4. Kroetz DL.: Genomics and proteomics in drug discovery and development. Millenial World Congress of Pharmaceutical Sciences. San Francisco (CA) 2000 April 16-20.
5. Zurlinder J.: Pharmacogenomics: tailoring the drug to the patient. Nurs Spectr 1998; 8: 10-24.
6. Chen S., Wedlund PJ.: Correlation between cytochrome P 450 2D6 (CYP2D6) genotype and phenotype. Acta Pharmacol Sin 1999; 20: 586-588.
7. Radomski KM., Bush BA., Ensom MHH.: Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugs. Ann Pharmacother 1998; 32: 170-175.
8. Chen S., Chou WH., Blouin RA., et al: The cytochrome P 450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522-534.
9. Bauman JL, Schoen MD. Arrhythmias. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, CT: Appleton and Lange; 1999: 232-64.
10. Johnson JA, Parker RP, Geraci SA. Heart Failure. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, CT: Appleton and Lange; 1999: 153-81.
11. Hanratly CG., McGlinchey P., Johnston GD., Passmore AP.: Differential pharmacokinetics of digoxin in elderly patients. Drugs and Aging 2000; 17(5): 353-362.
12. http://www.globalrph.com. [Accessed 2003 April 15]
13. Lu AYH.: Drug-Metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug metabolism and disposition 1998; 26(12): 1217-1222.
14. Hammerlein A., Derendorf H., Lowenthal DT.: Pharmacokinetic and pharmacodynamic changes in the elderly: clinical implications clin pharmacokinet 1998; 35: 49-64.
15. Shammas FV., Dickstein K.: Clinical pharmacokinetics in heart failure: an update review. Clin pharmacokinet 1988; 15: 94-113.
16. Meissner K, Sperker B, Karsten C, Schwabedissen HM, Seeland U, Böhm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, Warzok R, Siegmund W, Cascorbi I, Wendt M, and Kroemer HK. Expression and Localization of P-glycoprotein in Human Heart: Effects of Cardiomyopathy. J. Histochem. Cytochem., October, 2002; 50: 1351-1356.
17. Hudson M., Pilote L.: Digoxin for the treatment of heart failure (Notes for the editor). N Eng J Med 2003; 348: 661.
18. Modasini MR. Krabenbubl S., Schlienger RG.: Appropriateness of digoxin level monitoring. Swiss Med Wkly 2002; 132: 506-512.
19. th London: Pharmaceutical Press; 2002:526-60
20. http://www.drug.com/drug_interactions.html [Accessed 2006 April 5]
21. Mallet L., Brooks PJ.: Monitoring digoxin in the elderly. CRJ-RPC 1990; 168-191.
22. Mason GD., Winter ME.: Appropriateness of sampling times for therapeutic drug monitoring. Am J Hosp Pharm 1984; 41: 1796-1801.
23. Anderson AC., Hodges GR., Barnes WG.: Determination of serum gentamicin sulfate levels. Arch Intern Med 1976; 136: 785-787.
24. Slaughter RL., Schneider PJ., Visconti JA.: Appropriateness of the use of serum digoxin and digitoxin assays. Am J Hosp Pharm 1978; 35: 1376-1379.
25. Aronson JK.: Indications for the measurement of plasma digoxin concentrations. Drug 1983; 26: 230-242.
26. Matzuk MM., Shlomchik M., Shaw LM.: Making digoxin therapeutic drug monitoring more effective. Ther Drug Monit 1991; 13: 215-219.
27. Clague HW., Tmum-Barima Y., Carruthers SG.: An audit of requests for therapeutic drug monitoring of digoxin: problems and pitfalls. Ther Drug Monit 1983; 5: 249-254.
28. Gottesman MM., Pastan I.: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
29. Schinkel AH., Wagenaar E., vanDeemter L., Mol CA., Borst P.: Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A. J Clin Invest 1995; 96: 1698-1705.
30. Endicott JA., Ling V.: The biochemistry of P-glycoprotein mediated multi drug resistance. Annu Rev Biochem 1989; 58: 137-171.
31. Hoffmeyer S., Burk O., vonRichter O., Arnold HP., Brockmoller J., Johne A., et al.: Functional polymorphisms of the human multi drug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-3478.
32. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N, Ahmed SME and Mizugaki M. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. BJCP 2003; 55 (6):560-9
33. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., Schaffeler E., Eichelbaum M., Brinkmann U., Roots I.: Frequency of single nucleotide polymorphisms (SNPs) in the P-glycoprotein drug transporter MDR-1 gene in Caucasians. Clin Pharmacol Ther 2001; 69: 169-174.
34. Ameyaw MM., Regateiro F., Li T., Liu X., Tariq M., Mobarek M., Thornton N., Fotayan GO., Githang'a J., Indalo A., Ofori-Adjei D., Price-Evans D., McLeod HL.: MDR-1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11: 217-221.
35. Schaeffeler E., Eichelbaum E., Brinkmann U., Penger A., A sante-Poku S., Zanger UM., Schwab M.: Frequency of C3435T polymorphism of MDR-1 gene in African people. Lancet 2001; 358: 383-384.
36. Kin RB., Leake BF., Choo EF., Dresser GK., Kubba SV., Schwarz UI., Taylor A., Xie HG., McKinsey J., Zhou S., Lan LB., Schuetz JD., Schuetz EG., Wilkinson GR.: Identification of functionally variant MDR-1 alleles among European Americans and African American. Clin Pharmacol Ther 2001; 70: 189-199.
37. Fromm MF.: The influence of MDR-1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-1310.
38. Verstuyft C., Schwab Mathias, Schaeffeler E., Kerb R., Brinkmann U., Jaillon P., Funck-Brentano C., Becquemont L.: Digoxin pharmacokinetics and MDR-1 genetic polymorphism. Eur J Clin Pharmacol 2003; 58: 809-812.
39. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N. Sakai T., et al.: MDR-1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese Subjects. Pharm Res 2001; 18: 1400-1404.
40. Kurata Y., Ieiri I., Kimura M., Morita T., Irie S., Urae A., Ohdo S., Ohtani H., Sawada Y., Higuchi S., Otsubo K.: Role of human MDR-1 gene polymorphism in bioavailability and interaction of digoxin a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209-219.
41. Kerb R., Aynacioglu AS., Brockmoller J., Schlagenhaufer R., Bauer S., Szekeres T., Hamwi A., Fritzer-Szekeres M., Baumgartner C., Ongen HZ., Guzelbey P., Roots I., Brinkmann U.: The predictive value of MDR-1, CYP2C9 and YP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenetics 2001, 1: 204-210.
42. Balram C., Sharma C., Sivathasan C., Lee EJD.: Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: Pheotypic-genotypic correlates. Br J Clin Pharmacol 2003; 56: 78-83.
43. Uretsky BF., Young JB., Shahidi FE, et al: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial PROVED investigation group. J Am Coll Cardiol 1993; 22: 955-962.
44. Packer M., Gheorghiade M., Young JB, et al.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin conversing enzyme inhibitors: RADIANCE study. N Engl J Med 1993; 329: 1-7.
45. Rawles JM., Metcalfe MJ., Jennings K.: Time of occurrence duration and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J 1990; 63(4): 225-227.
46. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336; 525-533.
47. Guyatt GH., Sullivan MJJ., Fallen El., et al.: A controlled trial of digoxin in congestive heart failure. Am J Cardiol 1998; 61: 371-375.
48. Stanulla M., Schaeffeler E., Schrappe M., Arens S., Rathmann A., Welte K., Eichelbaum M., Zanger UM., Schwab M.: An association between the MDR1 C3435T polymorphism and CNS relapse in child- hood ALL, Eur J Clin Pharmacol 2001; 57: A28.
49. Fellay J., Marzolini C., Meaden ER., Back DJ., Buclin T., Chove J-P.: Decosterd LA, Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel AH., Vernazza P., Eap CB., Telenti A.: Response to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug transport-1: a pharmacogenetics study. Lancet 2002; 359: 30-36.